Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab.
Fernando MagroSusana LopesMarco SilvaRosa CoelhoFrancisco PortelaDiogo BranquinhoLuís CorreiaSamuel FernandesMarília CravoPaulo CaldeiraHelena Tavares de SousaMarta PatitaPaula LagoJaime RamosJoana AfonsoIsabel RedondoPatrícia MachadoGeorge PhilipJoanne LopesFátima CarneiroPublished in: Therapeutic advances in gastroenterology (2019)
sST2 may be a surrogate biomarker of UC activity and therapeutic response as it correlates with endoscopic and clinical activity at W6 of golimumab treatment, and subjects with endoscopic and histological activity at W6 had higher baseline ST2 levels.